Organization: Genesys Capital

Fusion raises US $25 million for cancer targeting technology

Fusion Pharmaceuticals Inc, a spin out of the Centre for Probe Development and Commercialization (CPDC), has secured US$25 million in series ‘A’ financing to support and accelerate development of new next-generation therapeutics that precisely target cancer cells.

Allostera raised $17 million in VC financing

Montreal-based Allostera Pharma Inc has raised $17 million in series ‘A’ financing to develop a new class of drugs based on the firm’s proprietary Module X platform technology. So-called allosteramers use modified peptides with highly specific targets that can be developed rapidly and can be taken orally, which may make them more widely accepted than…